UNC Department of Obstetrics & Gynecology
Document Actions
Research
The Gynecologic Oncology Division:
- has an integrated approach to cancer care and research. We have a track record of taking clinical questions and translating them into clinical trials. Several of our laboratory endeavors have lead to clinical trials in the hopes that we will be able to improve the outcomes of our patients who have gynecologic malignancies.
- Is active participants in the Gynecologic Oncology Group which is our specialty's clinical trial organization. In addition, we partner with our colleagues in the pharmaceutical industry in order to offer our patients novel therapies in a timely fashion.
- Has collaborations with the UNC Lineberger Comprehensive Cancer Center allow us to collaborate with thought leaders and scientists in other disciplines to move forward with research in gynecologic malignancies. Our Phase I team at UNC is multidisciplinary thereby allowing our patients to benefit from novel treatments when other conventional options have failed.
- Is active in basic science, translational and clinical research with laboratories in MacNider and at the UNC Lineberger Comprehensive Cancer Center. Basic science and translational research interests include (1) novel targeted therapies for endometrial cancer and their interactions with critical cell signaling pathways implicated in the pathogenesis of this disease and (2) gene expression profiling of endometrial and ovarian cancer tumors. Clinical research interests are vast but include retrospective analyses of treatment strategies for ovarian and endometrial cancers and the application of robotic surgery to gynecologic malignancies.
Grants:
Ongoing Research Support:
University of North Carolina at Chapel Hill, University
Cancer Research Fund (UCRF) September 2008 – August 2010
A Molecular Pathway to Therapeutic Intervention and Individualized Treatment for Endometrial Cancer
Vickie Bae-Jump, Principal Investigator, Paola Gehrig, Co-Investigator,
Linda Van Le, Co-Investigator
Cephalon:
Phase II Trial of Trisenox in women with recurrent endometrial cancer 12/08 – 12/09
Paola Gehrig, Principal Investigator
National Cancer Institute
Centers of Cancer Nanotechnology Excellence, 3/08 – 3/09
Paola Gehrig, Co-Investigator; Zamboni, Co-PI
Pilot Study Evaluating Phenotypic Measures of the Reticuloendothelial System as Predictors of Doxil Pharmacokinetic and Pharmacodynamic Disposition in Patients with Refractory Ovarian Cancer
NIH/NCRR 1KL2RR025746-01
Etta Pisano, Principal Investigator; Vickie Bae-Jump, Scholar
Roadmap Multidisciplinary Clinical Research Career Development K12 Scholar, July 2007-2010
“Preclinical in vitro and in vivo evaluation of mTOR inhibitors in combination with multiple chemotherapeutic agents used for the treatment of endometrial cancer”
University of North Carolina at Chapel Hill University
Research Council Award, December 2007-November 2009
Vickie Bae-Jump, Principal Investigator
“Rationale for mTOR Inhibitors and Progestins as a Potential Combined Therapeutic Strategy for Endometrial Cancer”
University of North Carolina at Chapel Hill
The Excellence Fund of The Medical Foundation, July 2008-June 2009
Vickie Bae-Jump, Principal Investigator
“The Relationship between Obesity, Insulin Resistance and Innate Immunity in Endometrial Cancer”
Marsha Rivkin Center for Ovarian Cancer Research
Pilot Project Grant, June 2008-May 2009
Van Dyke, Principal Investigator; Vickie Bae-Jump, Co-Investigator
“A Pathway to Therapeutic Treatment and Early Detection of Human Epithelial Ovarian Cancer”
Center for Environmental Health & Susceptibility (CEHS)
Standard Pilot Projects Program, April 2008-March 2009
Sampey, Co-Principal Investigator; Vickie Bae-Jump, Co-Investigator
“Preclinical Evaluation of Genistein and Soy Extract in Combination with Conventional Cytotoxic and Hormonal Treatment Regimens for Endometrial Cancer”